In patients with behavioural variant frontotemporal dementia, a single dose of intranasal oxytocin significantly improved Neuropsychiatric Inventory scores on the evening of dosing versus placebo and versus baseline.
In plain wordsIn people with behavioural variant frontotemporal dementia, one nasal oxytocin dose improved caregiver-rated behaviour that evening compared with placebo and with baseline.
- Peptide
- Oxytocin
- Outcome
- Direction not reportedNeuropsychiatric Inventory score on the evening of administration
- Study
n = 20
- Comparator
- Placebo
- Outcome group
- Psychiatric symptoms · Nervous system and cognition
- Studied dose
- 24 IU · intranasal · single doseAs given in this study (human).
Source sentences
A significant improvement in scores on the Neuropsychiatric Inventory was observed on the evening of oxytocin administration compared with placebo and compared with baseline ratings.
1 context sentence(design, population, supporting numbers)
In a double-blind, placebo-controlled, randomized cross-over design, 20 patients with behavioural variant frontotemporal dementia received one dose of 24 IU of intranasal oxytocin or placebo and then completed emotion recognition tasks known to be affected by frontotemporal dementia and by oxytocin.